Application Note

Duodenum Intestine-Chip For Toxicity Assessment

Source: Emulate
GettyImages-474279266 Yellow capsules

Gastrointestinal (GI) toxicity stands as one of the most prevalent clinical side effects triggered by therapeutics and other xenobiotics. Enhancing the ability to accurately predict the risk of intestinal toxicity during preclinical drug development holds promise for improving the quality of drug treatments and minimizing unwanted side effects in the clinic.

Here, we review how the Duodenum Intestine-Chip was applied to evaluate the toxicity of indomethacin, a known GI toxicant. The Duodenum Intestine-Chip effectively mimics intestinal tissue and replicates in vivo-like physiology for use in assessing drug safety. The co-culture model incorporates organoid-derived primary epithelial cells and primary human small intestinal microvascular endothelial cells (siHIMECs). Indomethacin safety was assessed across multiple endpoints, including I-FABP accumulation, LDH release, morphology, and barrier function. This technology holds potential for future applications assessing drug absorption, drug-drug interactions, and donor-to-donor variability in patient-derived cells.

access the Application Note!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.

Subscribe to Drug Discovery Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Drug Discovery Online